Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2014

View Archived Issues

Takeda Pharmaceutical discloses new CH24H inhibitors

Astex Therapeutics patents novel IAP inhibitors for cancer

Novel biomarkers for Cushing's syndrome, HDR syndrome and MEN1 identified

Preclinical and early clinical data presented for prodrug of Debio-1452

Enantiomer switching of an existing drug unveils novel mechanism of action against cancer cells

GSK-2339345 proves safe in phase I trials for chronic cough

Kymab secures funding to advance clinical development of antibody therapeutics

FDA orphan status granted to diazoxide choline

ADC Therapeutics and MedImmune to advance ADCT-401 into clinic

Phase II results presented for relamorelin in chronic constipation, diabetic gastroparesis

Cellceutix reports promising findings for brilacidin in diabetic wound model

Sorrento Therapeutics discloses new antibodies for S. aureus infection

KineMed and CHDI Foundation expand Huntington's disease collaboration

Provista Diagnostics initiates clinical study of blood assay for breast cancer

Senesco Technologies completes acquisition of Fabrus

Agenix to sell its tenofovir prodrug

BioAlliance's Livatag receives FDA fast track designation

Ophthotech licenses ex-U.S. rights to Fovista to Novartis

Bioenergenix discloses novel hPASK inhibitors

Dainippon Sumitomo Pharma synthesizes new mGlu5 receptor modulators

MOR-208 receives FDA and EMA orphan drug designations

AADi in-licenses nanotechnology-based drug

Merck KGaA proposes global alliance against schistosomiasis

GSK and Genmab report topline data from pivotal head-to-head study of ofatumumab

Isis Pharmaceuticals begins phase I study of ISIS-PKK-Rx

Takeda achieves FDA approval for vedolizumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...